New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2013
16:09 EDTINOInovio Pharma initiated with an Overweight at Piper Jaffray
Target $1.
News For INO From The Last 14 Days
Check below for free stories on INO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
11:22 EDTINOOptions with decreasing implied volatility
Subscribe for More Information
July 29, 2014
11:46 EDTINOOptions with decreasing implied volatility
Options with decreasing implied volatility: INO PBYI ANGI MLNX INFN TTS QLIK DECK SKX CRUS
July 28, 2014
11:18 EDTINOOptions with decreasing implied volatility
Subscribe for More Information
July 25, 2014
11:08 EDTINOOptions with decreasing implied volatility
Options with decreasing implied volatility: INO PBYI MLNX DECK INFN CMG QLIK LKX ANGI NFLX
July 24, 2014
11:15 EDTINOInovio upgraded to Buy from Hold at Aegis
Aegis upgraded Inovio to Buy following positive top-line data from the clinical trial of its lead human papillomavirus DNA-based vaccine, VGX-3100, in patients with high-grade cervical dysplasia. Price target raised to $19 from $10.
10:26 EDTINOOptions with decreasing implied volatility
Subscribe for More Information
July 23, 2014
16:47 EDTINOInovio files $175M mixed securities shelf
13:21 EDTINOInovio says ITT analysis achieved statistical significance in VGX-3100 trial
Subscribe for More Information
11:21 EDTINOOptions with decreasing implied volatility
Options with decreasing implied volatility: INO SHPG IRBT CMG LXK PSEC CROX ATHN VMW
11:08 EDTINOHigh option volume stocks
Subscribe for More Information
09:44 EDTINOInovio price target raised to $29 from $26 at Piper Jaffray
Subscribe for More Information
09:20 EDTINOInovio's VGX-3100 for cervical dysplasia shows positive Phase II results
Inovio Pharmaceuticals announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 associated with human papillomavirus types 16 or 18. Treatment with VGX-3100 resulted in histopathological regression of CIN2/3 to CIN1 or no disease, meeting the study's primary endpoint. The trial demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected in subjects who received VGX-3100 compared to those who received placebo.
July 21, 2014
07:11 EDTINOInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use